Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 5 of 6 for:    LY3214996

LY3214996 +/- HCQ in Pancreatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04386057
Recruitment Status : Recruiting
First Posted : May 13, 2020
Last Update Posted : June 29, 2020
Sponsor:
Collaborator:
Eli Lilly and Company
Information provided by (Responsible Party):
Brian Wolpin, MD, MPH, Dana-Farber Cancer Institute

Brief Summary:
This study is evaluating the safety and efficacy of combining the study drug LY3214996 with hydroxychloroquine sulfate (HCQ) in patients with advanced pancreatic cancer.

Condition or disease Intervention/treatment Phase
Pancreatic Cancer Advanced Cancer Drug: Hydroxychloroquine Sulfate Drug: LY3214996 Phase 2

Detailed Description:
  • This is an open label, randomized, two arm, phase II with safety lead- in study exploring the anti-tumor activity of the extracellular signal-regulated kinase (ERK) inhibitor LY3214996 with and without hydroxychloroquine (HCQ) in patients with advanced pancreatic cancer.
  • The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.

    • The safety lead-in will test the safety of a combination of investigational drugs and also try to define appropriate dosage. The names of the study drugs involved in this study are:

      • LY3214996
      • Hydroxychloroquine Sulfate (HCQ)
    • Following completion of a brief combination treatment safety lead-in cohort, participants will be randomized 1:1 for enrollment to one of two treatment arms:

      • Arm 1: receiving combination treatment with LY3214996 and HCQ
      • Arm 2: receiving monotherapy treatment with LY3214996

It is expected that about 52 people will take part in this research study

The U.S. Food and Drug Administration (FDA) has not approved LY3214996 as a treatment for any disease.

The U.S. Food and Drug Administration (FDA) has not approved HCQ for your specific disease but it has been approved for other uses.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 52 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Trial of ERK Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic Cancer
Actual Study Start Date : May 27, 2020
Estimated Primary Completion Date : March 18, 2022
Estimated Study Completion Date : September 19, 2022


Arm Intervention/treatment
Experimental: Safety Lead-In Cohort

The research study procedures include screening for eligibility and study treatment. Study treatment will include evaluations, biopsies, and follow up visits. A treatment cycle will be defined as 28 consecutive days. Treatment will be administered on an outpatient basis.

Test the safety of study drugs in combination and define dose levels.

  • LY3214996
  • HCQ
Drug: Hydroxychloroquine Sulfate
HCQ will be administered by mouth twice daily continuously throughout each treatment per 28 day cycle
Other Names:
  • Plaquenil®)
  • HCQ

Drug: LY3214996
LY3214996-daily oral dosage per protocol per 28 day cycle

Experimental: LY3214996 and HCQ Combination

The research study procedures include screening for eligibility and study treatment. Study treatment will include evaluations, biopsies, and follow up visits. A treatment cycle will be defined as 28 consecutive days. Treatment will be administered on an outpatient basis. Combined dosage per determined Lead-In Cohort

  • LY3214996
  • HCQ
Drug: Hydroxychloroquine Sulfate
HCQ will be administered by mouth twice daily continuously throughout each treatment per 28 day cycle
Other Names:
  • Plaquenil®)
  • HCQ

Drug: LY3214996
LY3214996-daily oral dosage per protocol per 28 day cycle

Experimental: LY3214996-Monotherapy

The research study procedures include screening for eligibility and study treatment. Study treatment will include evaluations, biopsies, and follow up visits. A treatment cycle will be defined as 28 consecutive days.Treatment will be administered on an outpatient basis.

-LY3214996

Drug: LY3214996
LY3214996-daily oral dosage per protocol per 28 day cycle

Experimental: Cross Over Arm

Participants who are enrolled to Arm 2 who experience radiologic disease progression on monotherapy will have the option to cross-over to receive treatment with the combination. Crossover will occur at the treating investigator's discretion following consultation and approval from the overall principal investigator. Combined dosage per determined Lead-In Cohort

  • LY3214996
  • HCQ
Drug: Hydroxychloroquine Sulfate
HCQ will be administered by mouth twice daily continuously throughout each treatment per 28 day cycle
Other Names:
  • Plaquenil®)
  • HCQ

Drug: LY3214996
LY3214996-daily oral dosage per protocol per 28 day cycle




Primary Outcome Measures :
  1. Disease control rate (DCR) [ Time Frame: 28 Months ]
    Anti-tumor activity will be measured via disease control rate (DCR), which will be defined as the proportion of patients with complete response (CR), partial response (PR) or stable disease (SD) that persists for ≥ 4 months.

  2. Dose Limiting Toxicity-Lead In [ Time Frame: 28 Days ]
    Dose Limiting Toxicity-Lead In


Secondary Outcome Measures :
  1. Objective response rate (ORR) [ Time Frame: 28 Months ]
    Objective response rate (ORR)

  2. Progression-free survival (PFS) [ Time Frame: time from randomization (or registration) to the earlier of progression or death due to any cause. Participants alive without disease progression are censored at date of last disease evaluation up to 28 Months ]
    Progression-free survival (PFS)

  3. Overall survival (OS) [ Time Frame: Overall Survival (OS) is defined as the time from randomization (or registration) to death due to any cause, or censored at date last known alive up to 34 Months ]
    Kaplan and Meier to assess Overall survival (OS)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Participants must have histologically or cytologically confirmed adenocarcinoma or poorly differentiated carcinoma of the pancreas.
  • Age ≥ 18 years.
  • ECOG performance status ≤ 1
  • Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for nonnodal lesions and short axis for nodal lesions) as ≥ 20 mm with conventional techniques or as ≥ 10 mm with spiral CT scan, MRI, or calipers by clinical exam.
  • Participants must have received at least one but no more than two prior lines of systemic therapy for metastatic pancreatic cancer. Perioperative treatment (chemotherapy and/or radiation) is not considered a prior line of therapy.
  • Participants must have adequate organ and marrow function as defined below:

    • Absolute Neutrophil Count ≥ 1,500/mcL
    • Platelet Count ≥ 100,000/mcL
    • Total Bilirubin ≤ 1.5 × institutional upper limit of normal (ULN)
    • AST (SGOT) / ALT(SGPT) ≤ 2.5 × institutional ULN, OR
    • AST (SGOT) / ALT (SGPT) ≤ 5 × institutional ULN if elevation is a result of metastases
    • Creatinine ≤ 1.5 × institutional ULN, OR
    • Creatinine Clearance ≥ 60 mL/min/1.73 m2 for participants with creatinine levels above 1.5 × institutional normal (calculated via the Cockcroft-Gault equation)
  • The effects of LY3214996 or HCQ on the developing human fetus are unknown. For this reason and because anti-cancer agents are known to be teratogenic, women of child bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of LY3214996 or HCQ administration.
  • Ability to understand and the willingness to sign a written informed consent document.
  • Ability to swallow and retain oral medication
  • Baseline QTcB of ≤ 470 msec on screening EKG.
  • Participants must be able and willing to undergo the pre-treatment biopsy procedure, and have a cancer site amenable to biopsy.

Exclusion Criteria:

  • Participants with pancreatic histologies other than adenocarcinoma or poorly differentiated carcinoma, such as neuroendocrine or acinar cell carcinoma.
  • Participants who have received a prior MAPK pathway inhibitor, including but not limited to LY3214996.
  • Participants who have had systemic chemotherapy, other investigational therapy, or immunotherapy within 3 weeks prior to the first dose of study medication.
  • Participants who have received oral tyrosine kinase inhibitors (TKIs) within 5 half-lives of the first dose of study medication.
  • Participants who have received radiation therapy within 2 weeks prior to the first dose of study medication.
  • Participants who have had major surgery within 4 weeks prior to the first dose of study medication.
  • Participants with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to LY3214996 or HCQ. Individuals with a history of a different malignancy are ineligible with the following exceptions: individuals who have been treated and are disease-free for a minimum of 3 years prior to study enrollment, or individuals who are deemed by the treating investigator to be at low risk for disease recurrence. Additionally, individuals with the following cancers are eligible if diagnosed and curatively treated within the past 3 years: basal or squamous cell carcinomas of the skin, and breast or cervical carcinomas in situ.
  • Uncontrolled intercurrent illness including, but not limited to: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Pregnant women are excluded from this study because LY3214996 and HCQ are agents with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with LY3214996 or HCQ, breastfeeding should be discontinued if the mother is treated with LY3214996 or HCQ. A negative serum pregnancy test is required for women of childbearing potential prior to the first dose of study medication.
  • Participants who are known to be seropositive for human immunodeficiency virus (HIV) or hepatitis B or C.
  • Participants with a history or findings of central or branch retinal artery or venous occlusion with significant vision loss, or other retinal diseases causing visual impairment or would likely cause visual impairment over the time period of the study, as assessed by an ophthalmologist.
  • Participants with a known personal or family history of long QT syndrome.
  • Participants with known glucose-6-phosphate dehydrogenase (G6PD) deficiency.
  • Participants who are known at the time of trial enrollment to require concomitant treatment with strong CYP3A4 inhibitors or inducers. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently updated medical reference.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04386057


Contacts
Layout table for location contacts
Contact: GI Clinical Research Line 617-632-5960 DFCIGCCRNRS@partners.org
Contact: DFCI Clinical Trials Hotline 877-DF-TRIAL

Locations
Layout table for location information
United States, Massachusetts
Massachusetts General Hospital Cancer Center Recruiting
Boston, Massachusetts, United States, 02114
Contact: Colin Weekes, MD    617-724-4000    CDWEEKES@Partners.org   
Principal Investigator: Colin Weekes, MD         
Dana-Farber Cancer Institute Recruiting
Boston, Massachusetts, United States, 02115
Contact: GI Research Line    617-632-5960      
Contact: Kim Perez, MD    617-632-6491    Kimberly_Perez@DFCI.HARVARD.EDU   
Principal Investigator: Brian Wolpin, MD, PHD         
Sponsors and Collaborators
Brian Wolpin, MD, MPH
Eli Lilly and Company
Investigators
Layout table for investigator information
Principal Investigator: Brian Wolpin, MD, PHD Dana-Farber Cancer Institute
Layout table for additonal information
Responsible Party: Brian Wolpin, MD, MPH, Sponsor Investigator, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier: NCT04386057    
Other Study ID Numbers: 19-529
First Posted: May 13, 2020    Key Record Dates
Last Update Posted: June 29, 2020
Last Verified: June 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Time Frame: Data can be shared no earlier than 1 year following the date of publication
Access Criteria: Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Brian Wolpin, MD, MPH, Dana-Farber Cancer Institute:
Pancreatic Cancer
Advanced Cancer
Extracellular Signal-Regulated Kinases
Cell Growth Inhibitors
Additional relevant MeSH terms:
Layout table for MeSH terms
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Hydroxychloroquine
Antimalarials
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antirheumatic Agents